Caley Castelein - 25 Oct 2023 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Purchase	$50,694	+4,200	+0.85%	$12.07	500,719	25 Oct 2023	Direct	F1
transaction	TALS	Common Stock	Purchase	$229,890	+15,800	+3.2%	$14.55^*	516,519	27 Oct 2023	Direct	F2
holding	TALS	Common Stock						458,039	25 Oct 2023	By KVP Capital, LP	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.82 to $12.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	These shares are held by KVP Capital, LP ("KVP"). The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.